As of Sep 30
| +0.16 / +3.11%|
The 8 analysts offering 12-month price forecasts for Keryx Biopharmaceuticals Inc have a median target of 7.00, with a high estimate of 11.00 and a low estimate of 3.00. The median estimate represents a +31.83% increase from the last price of 5.31.
The current consensus among 11 polled investment analysts is to Hold stock in Keryx Biopharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.